Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosapride vs Domperidone plus twice-daily proton pump inhibitor in systemic sclerosis patients with gastro-esophageal reflux disease
TCTR20240509002Phase 3Recruiting
- Sponsor
- Thai Rheumatism Association
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in systemic sclerosis (SSc) and gastroesophageal reflux disease (GERD) comparing Mosapride + twice-daily proton pump inhibitor with Domperidone + twice-daily proton pump inhibitor (2 arms). Started May 2024; status: recruiting.
02
Drugs
mosapridedomperidone
03
Conditions
systemic sclerosis (SSc)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on TCTR20240509002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240509002.